Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.44 |
| ▸ | CA9 | Q16790 | 10/20 | 0.44 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646950 | 0.74 | KDM4E (0.36) | CA2CA12CA5ACA4CA5B | |
| SCHEMBL5767535 | 0.70 | KDM4E (0.44) | CA2CA9CA1CA12CA7 | |
| SCHEMBL11208011 | 0.68 | CA2 (0.44) | CA2CA9CA1CA12CA7 | |
| SCHEMBL3673621 | 0.68 | CA2 (0.44) | CA2CA9CA1CA12CA7 | |
| SCHEMBL7646065 | 0.67 | CA2 (0.43) | CA2CA9CA1CA12CA7 | |
| SCHEMBL3262642 | 0.66 | CA2 (0.53) | CA2CA9CA1CA12CA7 | |
| SCHEMBL202947 | 0.65 | CA2 (0.70) | CA2CA9CA1CA12CA7 | |
| SCHEMBL326634 | 0.65 | CA2 (0.44) | CA2CA9CA1CA12CA7 | |
| SCHEMBL6643829 | 0.64 | CA2 (0.38) | CA2CA9CA1CA12CA7 | |
| SCHEMBL8936399 | 0.64 | CA2 (0.46) | CA2CA9CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| EP-2590951-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | CA2 302/4885CA9 1021/4885CA1 1355/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | CA2 302/4885CA9 1021/4885CA1 1355/4885 |
| US-20130109696-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | CA2 175/4885CA9 1149/4885CA1 1251/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | CA2 302/4885CA9 1021/4885CA1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.